Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
26.91
+0.28 (+1.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,209,379
Open
26.58
Bid (Size)
26.16 (12)
Ask (Size)
27.00 (1)
Prev. Close
26.63
Today's Range
26.46 - 26.94
52wk Range
25.92 - 31.66
Shares Outstanding
388,132,400
Dividend Yield
2.97%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 12, 2024
Via
Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
June 05, 2024
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Via
InvestorPlace
Performance
YTD
-4.81%
-4.81%
1 Month
+1.09%
+1.09%
3 Month
-11.13%
-11.13%
6 Month
-1.21%
-1.21%
1 Year
-10.42%
-10.42%
More News
Read More
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
June 03, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
NASDAQ:RPRX: good value for what you're paying.
April 24, 2024
Via
Chartmill
Looking Into Royalty Pharma's Recent Short Interest
April 04, 2024
Via
Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
March 29, 2024
Via
Chartmill
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
May 28, 2024
Via
Benzinga
Exposures
Product Safety
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
May 28, 2024
Via
Investor's Business Daily
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
May 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
May 23, 2024
Via
Benzinga
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024
From
Royalty Pharma plc; Cytokinetics
Via
GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
May 20, 2024
Via
InvestorPlace
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Royalty Pharma Reports First Quarter 2024 Results
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
May 02, 2024
Via
Benzinga
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
April 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
April 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
3 Pharma Stocks to Sell in April Before They Crash & Burn
April 11, 2024
Via
InvestorPlace
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
April 09, 2024
Via
InvestorPlace
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
April 09, 2024
Via
InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
March 27, 2024
Via
InvestorPlace
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
February 29, 2024
Via
Chartmill
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.